Leukapheresis vs No Leukapheresis for AML Hyperleukocytosis: Meta-Analysis Results

1,406 patients from ten retrospective comparative studies contributed to the primary 30-day mortality analysis. Jamiel Reyes performed an updated systematic review and meta-analysis comparing leukapheresis versus no leukapheresis for hyperleukocytosis in acute myeloid leukemia, published on figshare in May 2026.

Use Cases

• Evaluate the association between leukapheresis and early mortality based on the pooled odds ratio (OR 0.94)
• Assess the quality of existing evidence based on the reported GRADE certainty and ROBINS-I risk of bias
• Identify research gaps based on the noted limitation of confounding by indication
• Review the methodology of systematic reviews in hematology based on the described search strategy and inclusion criteria

Strengths

• Includes data from 1,406 patients across ten studies
• Provides a specific odds ratio with confidence interval (OR 0.94, 95% CI 0.65–1.34)
• Follows a structured, prospectively registered review protocol (PROSPERO CRD420261351743)

Limitations

• Description metadata is limited; actual data quality requires manual inspection after download
• Column-level documentation is absent; field semantics must be inferred after download
• Most included studies were at serious risk of bias, and certainty of evidence was very low

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of comparative studies from MEDLINE, CENTRAL, ClinicalTrials.gov, Google Scholar, and citation searching.

Time Range

Studies searched from inception to March 2026.

Freshness

Last updated 2026-05-26 01:42:38; freshness should be verified